Cobicistat
============

**PD Dialyzability**: Unlikely

Pharmacokinetic Parameters [1]_ [2]_ [3]_
------------------------------------------

======= ======
/////// |pk|
======= ======
|pk1|   |v1|
|pk2|   |v2|
|pk3|   |v3|
|pk4|   |v4|
|pk5|   |v5|
|pk6|   |v6|
|pk7|   |v7|
======= ====== 

CAPD/CCPD Dosing: 
------------------

No dosing recommendation for PD population was found in literature. However, due to major hepatic metabolism and extensive protein binding, it is unlikely that dosing adjustment is required [1]_ [2]_. Cobicistat inhibits tubular secretion of creatinine, but does not affect actual glomerular function [2]_ [4]_. Note that cobicistat may not be available as a single entity product in Canada and the need for dose adjustment for other drugs in the combination product must be considered.

Literature Summary:
---------------------------

None identified. 

References
------------
.. [1] Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-672. 

.. [2] Gilead Sciences Canada, Inc. Product Monograph Tybost. Mississauga: Gilead Sciences Canada, Inc; 2016. 

.. [3] Tseng A. Selected properties of cobicistat. Immunodeficiency Clinic [Internet]. 2014 Dec [cited 2018 Jan 17]. 1-5. Available from www.hivclinic.ca.

.. [4] Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014;59(9):e96–138. 



.. |pk| replace:: Cobicistat
.. |pk1| replace:: Molecular Weight (Da)  
.. |pk2| replace:: Plasma Protein Binding (%)
.. |pk3| replace:: Volume of Distribution (L/Kg) 
.. |pk4| replace:: Hepatic Metabolism 
.. |pk5| replace:: Excreted Unchanged (%) 
.. |pk6| replace:: Half-Life; Normal Renal Function (hours)
.. |pk7| replace:: Half-Life; ESRD (hours) 
.. |v1| replace:: 776
.. |v2| replace:: 97 - 98
.. |v3| replace:: 77
.. |v4| replace:: CYP3A (Major), CYP2D6 (Minor)
.. |v5| replace:: 8
.. |v6| replace:: 3 - 4
.. |v7| replace:: Unknown